Lexeo Therapeutics, Inc. - Common Stock (LXEO)

Historical Holders from Q4 2023 to Q3 2025

Symbol
LXEO on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
72,987,327
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
49,357,693
Holdings value
$327,711,484
% of all portfolios
0.001%
Number of holders
109
Number of buys
76
Number of sells
-21
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lexeo Therapeutics, Inc. - Common Stock (LXEO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 9.99% -11.9% $65,914,563 +$10,720,599 7,291,434 +19.4% JANUS HENDERSON GROUP PLC 28 Nov 2025
BALYASNY ASSET MANAGEMENT L.P. 9.99% 0% $35,820,947 -$19,594,175 5,394,721 -35.4% Balyasny Asset Management L.P. 30 Sep 2025
CITADEL ADVISORS LLC 9.6% $24,536,915 5,334,112 Kenneth Griffin 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 6.9% $33,200,000 5,000,000 RA Capital Management, L.P. 20 Oct 2025
Affinity Asset Advisors, LLC 7.75% $12,713,495 4,252,005 Affinity Healthcare Fund, LP 28 May 2025
Vestal Point Capital, LP 7.5% +25% $27,338,885 +$5,903,896 4,117,302 +27.5% Vestal Point Capital, LP 30 Sep 2025
Paradigm Biocapital Advisors LP 5% $33,047,991 3,671,999 Paradigm BioCapital Advisors LP 13 Nov 2025
Frazier Life Sciences Public Fund, L.P. 5.7% -42% $14,137,948 -$11,165,787 3,073,467 -44.1% Frazier Life Sciences Public Fund, L.P. 30 Jun 2025
Longitude Capital Partners IV, LLC 3.8% $18,362,130 2,765,381 Longitude Capital Partners IV, LLC 30 Sep 2025
INTEGRATED CORE STRATEGIES (US) LLC 3.2% -42% $15,362,583 -$3,470,396 2,313,642 -18.4% Millennium Management LLC 30 Sep 2025
MIZUHO FINANCIAL GROUP INC 6.6% +13.3% $8,109,362 +$1,020,464 2,203,631 +14.4% Mizuho Financial Group, Inc. 31 Mar 2025
BlackRock, Inc. 4% -25% $14,368,977 +$2,295,902 2,168,444 +19% BlackRock, Inc. 30 Sep 2025
EVENTIDE ASSET MANAGEMENT, LLC 3.73% $4,544,189 1,234,834 Eventide Asset Management, LLC 31 Dec 2024
Omega Fund VI, L.P. 3.6% $4,359,460 1,184,636 Omega Fund VI, L.P. 31 Dec 2024
D1 Capital Partners L.P. 2.9% $3,601,439 978,652 D1 Capital Partners L.P. 31 Mar 2025
Adage Capital Management, L.P. 0.7% -85.4% $875,667 -$7,255,716 237,953 -89.2% Adage Capital Management, L.P. 31 Mar 2025

Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 49,357,693 $327,711,484 +$52,680,502 $6.64 109
2025 Q2 42,272,843 $169,997,165 +$59,022,508 $4.02 90
2025 Q1 28,007,948 $99,996,757 -$11,520,766 $3.47 88
2024 Q4 29,519,159 $194,192,987 -$4,086,062 $6.58 89
2024 Q3 29,735,114 $268,784,046 +$10,322,355 $9.04 67
2024 Q2 26,566,622 $426,105,401 +$55,254,655 $16.04 57
2024 Q1 23,119,889 $361,545,010 +$108,427,159 $15.68 54
2023 Q4 16,174,480 $217,090,546 +$217,090,546 $13.42 31